Search research articles
Contact Us
Filters
Showing results (21-30 of 525) with videos related to
Page
of 53
Sort By:
Statistics in Medicine
|
July 20, 2019
Information content of stepped-wedge designs when treatment effect heterogeneity and/or implementation periods are present
Jessica Kasza, Monica Taljaard, Andrew B Forbes
American Journal of Public Health
|
January 14, 2026
Myran et al. Respond
Daniel T Myran, Rosalie Pacula, Monica Taljaard
Clinical Trials (London, England)
|
March 3, 2016
Cluster-randomized trials: A closer look
Andrew D McRae, Monica Taljaard, Charles Weijer
Ethics & Human Research
|
November 2, 2020
Loopholes in the Research Ethics System? Informed Consent Waivers in Cluster Randomized Trials with Individual-Level Intervention
Alex John London, Monica Taljaard, Charles Weijer
The American Journal of Bioethics : AJOB
|
January 8, 2020
The Importance of Describing as Well as Defining Usual Care
Stuart G Nicholls, Merrick Zwarenstein, Monica Taljaard
Clinical Trials (London, England)
|
December 19, 2017
TwiC or treat? Are trials within cohorts ethically defensible?
Charles Weijer, Cory E Goldstein, Monica Taljaard
Statistics in Medicine
|
December 24, 2022
Power analyses for stepped wedge designs with multivariate continuous outcomes
Kendra Davis-Plourde, Monica Taljaard, Fan Li
Biometrics
|
October 31, 2021
Sample size considerations for stepped wedge designs with subclusters
Kendra Davis-Plourde, Monica Taljaard, Fan Li
The Medical Journal of Australia
|
February 15, 2019
The stepped wedge cluster randomised trial: what it is and when it should be used
Michael J Campbell, Karla Hemming, Monica Taljaard
Clinical Trials (London, England)
|
October 16, 2024
Are pragmatism and ethical protections in clinical trials a zero-sum game?
Hayden P Nix, Charles Weijer, Monica Taljaard
Page
of 53
Search research articles
Search
Showing results (21-30 of 525) with videos related to
Sort By:
Page
of 53
Statistics in Medicine
|
July 20, 2019
Information content of stepped-wedge designs when treatment effect heterogeneity and/or implementation periods are present
Jessica Kasza, Monica Taljaard, Andrew B Forbes
American Journal of Public Health
|
January 14, 2026
Myran et al. Respond
Daniel T Myran, Rosalie Pacula, Monica Taljaard
Clinical Trials (London, England)
|
March 3, 2016
Cluster-randomized trials: A closer look
Andrew D McRae, Monica Taljaard, Charles Weijer
Ethics & Human Research
|
November 2, 2020
Loopholes in the Research Ethics System? Informed Consent Waivers in Cluster Randomized Trials with Individual-Level Intervention
Alex John London, Monica Taljaard, Charles Weijer
The American Journal of Bioethics : AJOB
|
January 8, 2020
The Importance of Describing as Well as Defining Usual Care
Stuart G Nicholls, Merrick Zwarenstein, Monica Taljaard
Clinical Trials (London, England)
|
December 19, 2017
TwiC or treat? Are trials within cohorts ethically defensible?
Charles Weijer, Cory E Goldstein, Monica Taljaard
Statistics in Medicine
|
December 24, 2022
Power analyses for stepped wedge designs with multivariate continuous outcomes
Kendra Davis-Plourde, Monica Taljaard, Fan Li
Biometrics
|
October 31, 2021
Sample size considerations for stepped wedge designs with subclusters
Kendra Davis-Plourde, Monica Taljaard, Fan Li
The Medical Journal of Australia
|
February 15, 2019
The stepped wedge cluster randomised trial: what it is and when it should be used
Michael J Campbell, Karla Hemming, Monica Taljaard
Clinical Trials (London, England)
|
October 16, 2024
Are pragmatism and ethical protections in clinical trials a zero-sum game?
Hayden P Nix, Charles Weijer, Monica Taljaard
Page
of 53